Recurrent High Grade Glioma
Conditions
Interventions
Combination therapy group:Laser interstitial thermal therapy +Toripalimab
Procedure/Surgery:Laser interstitial thermal therapy alone
Sponsors
Beijing Tiantan Hospital,Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age range: 18-80 years old; 2.Patients with a histologically confirmed diagnosis of WHO CNS 5th edition grade 3 or 4 glioma who have previously received standard therapy. 3.No serious underlying diseases, blood routine, liver and kidney function, and coagulation function are basically normal; 4.Meet any of the following criteria: (1) Radiological progression according to the RANO criteria; (2) Evidence of disease progression on at least one imaging sequence other than T1 contrast-enhanced imaging; (3) Histopathological confirmation of tumor progression or recurrence. 5.All tumor lesions are located supratentorially, and the maximum short-axis diameter on the T1 contrast-enhanced sequence is = 30 mm. 6.Karnofsky Performance Status (KPS) >= 60, and the patient is considered able to tolerate interventional therapy. 7.No prior exposure to immune-related therapies. 8.The patient or legal guardian is able to understand the purpose of the study, comply with the study requirements, and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients who are likely to benefit from other treatments or unlikely to benefit from this study intervention. 2.Patients who have undergone craniotomy within the past 3 months. 3.Inability to undergo contrast-enhanced MRI examination. 4.Pregnant or lactating women, or women planning to become pregnant within 6 months. 5.Participation in another investigational drug or medical device trial within the past 3 months. 6.Presence of active or chronic autoimmune disease requiring immunosuppressive therapy (e.g., systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, or Crohn’s disease); history of active graft-versus-host disease (GVHD) or organ transplantation; active or uncontrolled infection; or other medical conditions that could interfere with treatment or outcome assessment. 7.Refusal or inability to complete study follow-up assessments. 8.Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ablation rate of lesions;Remaining volume of lesion;Overall Survival; | — |
Countries
China
Contacts
Public ContactDabiao Zhou
Beijing Tiantan Hospital,Capital Medical University
Outcome results
None listed